LADENBURG THALM/SH SH Begins Coverage on Dare Bioscience (NASDAQ:DARE)

Analysts at LADENBURG THALM/SH SH assumed coverage on shares of Dare Bioscience (NASDAQ:DARE) in a research note issued on Monday, Briefing.com reports. The brokerage set a “buy” rating and a $2.00 price target on the biotechnology company’s stock. LADENBURG THALM/SH SH‘s target price points to a potential upside of 209.65% from the stock’s current price.

Other equities research analysts have also issued research reports about the stock. Weiss Ratings lowered shares of Dare Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 16th. UBS Group set a $1.00 price objective on shares of Dare Bioscience in a research report on Monday, September 14th. Benchmark reaffirmed a “buy” rating on shares of Dare Bioscience in a research note on Monday, August 17th. Finally, HC Wainwright reiterated a “buy” rating on shares of Dare Bioscience in a report on Monday, August 17th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $5.00.

Dare Bioscience Stock Performance

NASDAQ:DARE opened at $0.65 on Monday. The firm has a market cap of $12.70 million, a PE ratio of -0.92 and a beta of 1.01. Dare Bioscience has a fifty-two week low of $0.62 and a fifty-two week high of $3.78. The business has a 50 day moving average price of $0.76 and a 200-day moving average price of $1.57.

Dare Bioscience (NASDAQ:DARE) last issued its earnings results on Thursday, August 13th. The biotechnology company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.10. Dare Bioscience had a negative net margin of 803.80% and a negative return on equity of 748.30%. The company had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.00 million. Research analysts predict that Dare Bioscience will post -0.69 EPS for the current year.

Dare Bioscience Company Profile

Daré Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies designed to address women’s health needs. Its research programs span contraception, vaginal and reproductive health, fertility, pregnancy and postpartum care, and menopause.

The company’s lead commercial product, XACIATO (clindamycin phosphate) vaginal gel 2%, is an FDA-approved prescription treatment for bacterial vaginosis. Daré’s development pipeline has also included Ovaprene, a hormone-free monthly intravaginal contraceptive, and investigational candidates intended to address contraception, sexual health, vaginal conditions and hormone-related disorders.

Daré Bioscience is headquartered in San Diego, California, and conducts development activities through collaborations with biotechnology, pharmaceutical and academic partners.